Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
Debates & Insight Sponsored OMA at NICE: Unlocking Access One Year On A new report by health economist Leela Barham examines how NICE’s Office for Market Access has progressed after a year in operation.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
